Chandra Prakash Belani

Chandra Prakash Belani

Auto-generated profile, based on publicly available information

Chandra Prakash Belani

Penn State Cancer Institute Penn State College of Medicine Hershey Pennsylvania USA

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2002 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
JSJoan H. Schiller
Joan H. Schiller
DHDavid Harrington
David Harrington
CBChandra P. Belani
Chandra P. Belani
CLCorey Langer
Corey Langer
ASAlan Sandler
Alan Sandler
DJDavid H. Johnson
David H. Johnson
We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced non–small-cell lung cancer. A total of 1207 patients with advanced non–small-cell lung cancer were randomly assigned to a reference regimen of cisplatin and paclitaxel or to one of three experimental regimens: cisplatin and gemcitabine, cisplatin and docetaxel, or carboplatin and paclitaxel. The response rate for all 1155 eligible patients was 19 percent, with a median survival of 7.9 months (95 percent confidence interval, 7.3 to 8.5), a 1-year survival rate of 33 percent (95 percent confidence interval, 30 to 36 percent), and a 2-year survival rate of 11 percent (95 percent confidence interval, 8 to 12 percent). The response rate and survival did not differ significantly between patients assigned to receive cisplatin and paclitaxel and those assigned to receive any of the three experimental regimens. Treatment with cisplatin and gemcitabine was associated with a significantly longer time to the progression of disease than was treatment with cisplatin and paclitaxel but was more likely to cause grade 3, 4, or 5 renal toxicity (in 9 percent of patients, vs. 3 percent of those treated with cisplatin plus paclitaxel). Patients with a performance status of 2 had a significantly lower rate of survival than did those with a performance status of 0 or 1. None of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non–small-cell lung cancer.

22 October 2003 in JAMA
Verified
Journal Article
Open access
PDF file
MKMark G. Kris
Mark G. Kris
RNRonald B. Natale
Ronald B. Natale
RHRoy S. Herbst
Roy S. Herbst
JLJr Thomas J. Lynch
Jr Thomas J. Lynch
DPDiane Prager
Diane Prager
AKAndrea C. Kay
Andrea C. Kay
More persons in the United States die from non–small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined.1 Each year, more than 60 000 persons develop stages IIIB and IV NSCLC; nearly all go on to die from metastatic spread. In addition, most individuals experience symptoms caused directly by lung cancer. These symptoms are often the first manifestations of the illness and increase in frequency and severity as the disease progresses. Cough, shortness of breath, weight loss, loss of appetite, and chest tightness impair the quality of lives already cut short by NSCLC. For patients with advanced lung cancer, physical well-being and changes in quality of life correlate with survival.2 Especially among patients with metastatic NSCLC, who are rarely cured, lessening lung cancer symptoms without adding burdensome adverse effects is an important goal of care. No anticancer therapy has been proven to be beneficial to persons seeking additional care after receiving 2 or more chemotherapy regimens.

1 October 2009 in The Lancet
Verified
Journal Article
Closed access
TCTudor Eliade Ciuleanu
Tudor Eliade Ciuleanu
TBThomas Brodowicz
Thomas Brodowicz
CZChristoph Zielinski
Christoph Zielinski
JKJoo Hang Kim
Joo Hang Kim
MKMaciej Krzakowski
Maciej Krzakowski
CBChandra P Belani
Chandra P Belani

15 August 2003 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
FFFrank Fossella
Frank Fossella
JPJose R. Pereira
Jose R. Pereira
JPJoachim von Pawel
Joachim von Pawel
APAnna Pluzanska
Anna Pluzanska
VGVera Gorbounova
Vera Gorbounova
CBChandra P. Belani
Chandra P. Belani
Purpose: To investigate whether docetaxel plus platinum regimens improve survival and affect quality of life (QoL) in advanced non–small-cell lung cancer (NSCLC) compared with vinorelbine plus cisplatin as first-line chemotherapy. Patients and Methods: Patients (n = 1,218) with stage IIIB to IV NSCLC were randomly assigned to receive docetaxel 75 mg/m2 and cisplatin 75 mg/m2 every 3 weeks (DC); docetaxel 75 mg/m2 and carboplatin area under the curve of 6 mg/mL • min every 3 weeks (DCb); or vinorelbine 25 mg/m2/wk and cisplatin 100 mg/m2 every 4 weeks (VC). Results: Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P = .044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]). The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients. Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P = .029). Median survival (9.4 v 9.9 months [for VC]; P = .657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC. Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens. Grade 3 to 4 anemia, nausea, and vomiting were more common (P < .01) with VC than with DC or DCb. Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL. Conclusion: DC resulted in a more favorable overall response and survival rate than VC. Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC. These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.

10 December 2007 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TOTaofeek Owonikoko
Taofeek Owonikoko
CRCamille C. Ragin
Camille C. Ragin
CBChandra P. Belani
Chandra P. Belani
AOAna B. Oton
Ana B. Oton
WGWilliam E. Gooding
William E. Gooding
SRSuresh S. Ramalingam
Suresh S. Ramalingam
Purpose: To study the burden and outcome of lung cancer in the elderly, particularly for patients aged 80 years and older. Patients and Methods: The national Surveillance, Epidemiology, and End Results database was analyzed for lung cancer outcomes during the period 1988 to 2003. A comparison was carried out between patients with lung cancer 80 years and older, 70 to 79 years, and younger than 70 years for demographics; stage distribution; 5-year relative survival; and survival based on histology, sex, race, stage, and treatment. The temporal trends in survival during the years 1988 to 1997 and 1998 to 2003 were also analyzed. Results: Of 316,682 patients eligible for the analysis, 45,912 (14%) were 80 years or older (ie, very elderly); 103,963 (33%) were 70 to 79 years; and 166,807 (53%) were younger than 70 years. The distribution by stage and histology was comparable for all the three groups. Overall survival rate at 5 years was lower in the very elderly (7.4% v 12.3% v 15.5%; P < .0001) across sex, histologic subtypes, stages, and racial categories. Patients aged 80 years or older were less likely to receive local therapy (no surgery or radiation) than younger patients (47% v 28% and 19% for the age subgroups ≥ 80 years, 70 to 79 years, and < 70 years, respectively). Overall outcomes for patients who underwent surgical therapy or radiation were comparable across the three age groups. In general, survival outcomes for the subgroup aged 70 to 79 years were similar to those of the subgroup aged 80 years and older who received single modality local therapy. Conclusion: Patients 80 years or older account for 14% (70 years or older accounted for 47%) of all lung cancers, are less likely to be subjected to surgery or radiation, and have inferior outcomes when compared with younger patients.

1 September 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
CBChandra P. Belani
Chandra P. Belani
HCHak Choy
Hak Choy
PBPhil Bonomi
Phil Bonomi
CSCharles Scott
Charles Scott
PTPatrick Travis
Patrick Travis
WCWalter J. Curran
Walter J. Curran
Purpose: This phase II noncomparative randomized trial was conducted to determine the optimal sequencing and integration of paclitaxel/carboplatin with standard daily thoracic radiation therapy (TRT), in patients with locally advanced unresected stage III non–small-cell lung cancer (NSCLC). Survival data were compared with historical standard sequential chemoradiotherapy data from the Radiation Therapy Oncology Group. Patients and Methods: Patients with unresected stages IIIA and IIIB NSCLC, with Karnofsky performance status ≥ 70% and weight loss ≤ 10%, received two cycles of induction paclitaxel (200 mg/m2)/carboplatin (area under the plasma concentration time curve [AUC] = 6) followed by TRT 63.0 Gy (arm 1, sequential) or two cycles of induction paclitaxel (200 mg/m2)/carboplatin (AUC = 6) followed by weekly paclitaxel (45 mg/m2)/carboplatin (AUC = 2) with concurrent TRT 63.0 Gy (arm 2, induction/concurrent), or weekly paclitaxel (45 mg/m2)/carboplatin (AUC = 2)/TRT (63.0 Gy) followed by two cycles of paclitaxel (200 mg/m2)/carboplatin (AUC = 6; arm 3, concurrent/consolidation). Results: With a median follow-up time of 39.6 months, median overall survival was 13.0, 12.7, and 16.3 months for arms 1, 2, and 3, respectively. During induction chemotherapy, grade 3/4 granulocytopenia occurred in 32% and 38% of patients on study arms 1 and 2, respectively. The most common locoregional grade 3/4 toxicity during and after TRT was esophagitis, which was more pronounced with the administration of concurrent chemoradiotherapy on study arms 2 and 3 (19% and 28%, respectively). Conclusion: Concurrent weekly paclitaxel, carboplatin, and TRT followed by consolidation seems to be associated with the best outcome, although this schedule was associated with greater toxicity.